

## References

1. Cervantes F. How I treat myelofibrosis. *Blood*. 2014;124:2636-2642.
2. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. *N Engl J Med*. 2012;366:799-780.
3. Harrison C, Kiladjan JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. *N Engl J Med*. 2012;366:787-798.
4. Pardanani A, Harrison CN, Cortes JE, et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. *JAMA Oncol*. 2015;1:643-651.
5. Mesa RA, Vannucchi AM, Mead A, et al. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. *Lancet Haematol*. 2017;4:e225-e236.
6. Mascarenhas J, Hoffman R, Talpaz M, et al. Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis. Randomized clinical trial. *JAMA Oncol*. 2018;652-659.
7. Verstovsek S, Gotlib J, Mesa RA, et al. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. *J Hematol Oncol*. 2017;10(1):156.
8. Harrison CN, Schapp N, Vannuchi AM, et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. *Lancet Hematol*. 2017;4:e317-e324.
9. Mesa RA, Kiladjan JJ, Catalano JV, et al. SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis. *J Clin Oncol*. 2017;35:3844-3850.
10. Newberry KJ, Patel K, Masarova L, et al. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. *Blood*. 2017;130:1125-1131.
11. Kuykendall AT, Shah S, Talati C, et al. Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. *Ann Hematol*. 2017;97:435-441.
12. Tefferi A, Cervantes F, Mesa R, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. *Blood*. 2013;122:1395-1398.
13. Harrison CN, Schaap N, Vannuchi AM, et al. Fedratinib (FEDR) in myelofibrosis (MF) patients previously treated with ruxolitinib (RUX): A reanalysis of the JAKARTA-2 study. ASCO 2019. Abstract 7057.
14. Harrison CN, Schapp N, Vannuchi AM, et al. Fedratinib induces spleen responses in patients with myeloproliferative neoplasm-associated intermediate- or high-risk myelofibrosis (MF) previously exposed to ruxolitinib (RUX), regardless of reason for discontinuing RUX. ASH 2019. Abstract 4165.
15. Harrison CN, Schaap N, Vannuchi AM, et al. Fedratinib Induces Spleen Responses and Reduces Symptom Burden in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Low Platelet Counts, who were Either Ruxolitinib-Naïve or were Previously Treated with Ruxolitinib. ASH 2019. Abstract 668.

16. Harrison CN, Schaap N, Vannuchi AM, et al. Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib. ASH 2019. Abstract 2207.
17. Mesa RA, Schaap N, Vannuchi AM, et al. Health-Related Quality of Life (HRQoL) in Patients with Myelofibrosis Treated with Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in the Randomized, Placebo-Controlled, Phase III JAKARTA Study. ASH 2019. Abstract 704.
18. Harrison CN, Vannuchi AM, Platzbecker U, et al. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY-2): a randomized, open-label, phase 3 trial. *Lancet Haematol*. 2018;5:e73-e81.
19. Economides MP, Verstovsek S, Pemmaraju N. Novel therapies in myeloproliferative neoplasms: beyond JAK inhibitors. *Curr Hematol Malig Rep*. 2019;14:460-468.
20. Asai A, Oshima Y, Yamamoto Y, et al. A novel telomerase template antagonist (GRN163) as a potential anticancer agent. *Cancer Res*. 2003;63:3931-3939.
21. Herbert BS, Gellert GC, Hochreiter A, et al. Lipid modification of GRN163, an N3'-->P5' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. *Oncogene*. 2005;24:5262-5268.
22. Mascarenhas J, Komrokji RS, Cavo M, et al. Imetelstat is effective treatment for patients with intermediate-2 or high-risk myelofibrosis who have relapsed on or are refractory to Janus kinase inhibitor therapy: results of a phase 2 randomized study of two dose levels. ASH 2018. Abstract 685.
23. Kuykendall A, Wan Y, Mascarenhas J, et al. Favorable overall survival of imetelstat-treated relapsed/refractory myelofibrosis patients compared with closely matched real world data. EHA 2019. Abstract PS1456.
24. Duffield JS, Lupher ML Jr. PRM-151 (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis. *Drug News Perspect*. 2010;23(5):305-315.
25. Verstovsek S, Talpaz M, Wadleigh M, et al. A randomized, double blind phase 2 study of 3 different doses of PRM-151 in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib. EHA 2019. Abstract S828.
26. Mascarenhas J, Kremyanskaya M, Hoffman R, et al. MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or "Add-on" to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis. ASH 2019. Abstract 670.
27. Harrison CN, Garcia JS, Mesa RA, et al. Results from a phase 2 study of navitoclax in combination with ruxolitinib in patients with primary or secondary MF. ASH 2019. Abstract 671.